-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FS4eZHexgW91d/Fgi2o5U+VyRG8MQVC2Q1BPr/g2Z+1kmzpyz0TUst0i2ztOAzX/ 1n+pUHjODvQ/BDGZM+tiIA== 0001104659-08-072112.txt : 20081120 0001104659-08-072112.hdr.sgml : 20081120 20081120161515 ACCESSION NUMBER: 0001104659-08-072112 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20081119 FILED AS OF DATE: 20081120 DATE AS OF CHANGE: 20081120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Price Kevin CENTRAL INDEX KEY: 0001440471 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 081204103 BUSINESS ADDRESS: BUSINESS PHONE: 44-0-4642-558-970 MAIL ADDRESS: STREET 1: C/O PHARMATHENE UK LTD, STREET 2: P.O. BOX 88, HAVERTON HILL ROAD CITY: BILLINGHAM TS23 1XN STATE: X0 ZIP: TS23 1XN ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 4 1 a4.xml 4 X0303 4 2008-11-19 0 0001326190 PHARMATHENE, INC PIP 0001440471 Price Kevin C/O PHARMATHENE UK LTD. P.O. BOX 88, HAVERTON HILL ROAD BILLINGHAM X0 TS23 1XN UNITED KINGDOM 0 1 0 0 President-Pharmathene UK, Ltd. Common Stock 2008-11-19 4 P 0 2500 0.95 A 2500 D Exhibit List Exhibit 24 - Confirming Statement /s/ Roland S. Chase, attorney in fact 2008-11-20 EX-24 2 ex-24.htm EX-24

Exhibit 24

 

CONFIRMING STATEMENT

 

 This Statement confirms that the undersigned has authorized and designated Jordan P. Karp, Christopher C. Camut, Jeffrey A. Baumel and Roland S. Chase (the “Authorized Signatories”), or any one or more of them, to execute and file on the undersigned’s behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned’s ownership of or transactions in securities of PharmAthene, Inc.  The authority of the Authorized Signatories  under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to his/her ownership of, or transactions in, securities of  PharmAthene, Inc., unless earlier revoked in writing.  The undersigned acknowledges that Authorized Signatories are not assuming any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

 

 

Dated:

November 20, 2008

 

 

 

Signed:

/s/ Kevin Price

 

 

 

Print Name:

Kevin Price

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----